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Abstract
Problem—CD300a is an immunomodulatory molecule of the immunoglobulin receptor
superfamily expressed in the leukocytes of myeloid and lymphoid lineages. However, its
biological function on CD8+ T lymphocytes remains largely unknown. This study was conducted
to assess the biological significance of CD300a expression in T lymphocytes and to determine
whether its expression in peripheral T lymphocytes changes in pregnant women presenting with
anti-fetal rejection.
Methods of Study—Microarray analysis was performed using total RNA isolated from
peripheral CD300a+ and CD300a− T lymphocytes. Flow cytometric analysis of the peripheral
blood samples of pregnant women and pathologic examination of the placentas were conducted.
Results—A large number of genes (N = 1,245) were differentially expressed between CD300a−
and CD300a+ subsets of CD8+ T lymphocytes, which included CCR7, CD244, CX3CR1, GLNY,
GZMB, GZMK, IL15, ITGB1, KLRG1, PRF1, and SLAMF7. Gene Ontology analysis of
differentially expressed genes demonstrated enrichment of biological processes such as immune
response, cell death, and signal transduction. CD300a expression in CD8+ T lymphocytes was
coupled to a more cytotoxic molecular signature. Of note, the proportion of CD300a+CD8+ T
lymphocytes increased in pregnant women with chronic chorioamnionitis (anti-fetal rejection of
the chorioamniotic membranes; P < 0.05).
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Conclusion—The findings of this study strongly suggest an increase of systemic T lymphocyte-
mediated cytotoxicity in pregnant women with chronic chorioamnionitis as a manifestation of
maternal anti-fetal rejection.
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Introduction
Tolerance of the fetus by the mother during pregnancy is essential for viviparity.1, 2
Biological characteristics such as separation of maternal circulation from fetal circulation3, 4
and expression of non-polymorphic HLA-G on trophoblasts5 are well-established
mechanisms protective of the fetus. In addition, a large body of evidence indicates that the
maternal immune system also undergoes alterations to avoid rejection of the semi-allogeneic
fetus, and a role for regulatory T lymphocytes has been emphasized recently.6–8 As T
lymphocytes play a key role in immune response, many investigators have studied changes
of peripheral T lymphocyte subsets in the context of maternal tolerance of the fetus.9–14
Several studies have noted that the proportion of peripheral CD8+ T lymphocytes either
increases or does not change during pregnancy,9–11, 13 while the absolute number of CD3+,
CD4+, and CD8+ T lymphocytes decreases during pregnancy.12–14 There are also other
reports showing that the expression of activation markers such as HLA-DR and CD25 in T
lymphocytes changes during pregnancy.9, 12 These observations overall strongly suggest
that pregnancy is associated with changes involving peripheral T lymphocyte numbers and
activation status.
CD300a is a leukocyte surface molecule of the immunoglobulin receptor (IgR) superfamily.
It has extracellular V-type Ig-like domains and a cytoplasmic domain with immunoreceptor
tyrosine-based inhibitory motifs (ITIM). CD300a can be detected on the surface of various
leukocyte populations such as monocytes, macrophages, granulocytes, dendritic cells, NK
cells, and T and B lymphocytes.15, 16 Among CD4+ T lymphocytes, CD300a expression is
mainly restricted to Th1 memory and effector cells.17 IFNγ-producing CD4+ T
lymphocytes are enriched in CD300a+ expressing cells, and stimulated CD4+ T
lymphocytes producing TNFαα and IL-2 are also largely positive for CD300a. Marked up-
regulation of T-box transcription factor Eomesodermin (Eomes) is another characteristic of
stimulated CD300a+CD4+ T lymphocytes.18 However, the biological significance of
CD300a expression on CD8+ T lymphocytes remains largely unknown.
Villitis of unknown etiology is a destructive inflammation of the placenta and a consequence
of maternal anti-fetal rejection.19 Infiltration of maternal CD8+ T lymphocytes into the fetal
chorionic villi is its characteristic feature, and we have found increased expression of
CD300a in villitis of unknown etiology. Increased expression of CD300a in villitis of
unknown etiology led us to think that CD300a-expressing CD8+ cells represent a
functionally distinct subset of T lymphocytes involved in maternal immune response against
the fetus during pregnancy.
This study was performed to assess the biological meaning of CD300a expression in CD8+
T lymphocytes using gene expression profiling. A further flow cytometric analysis of
peripheral blood samples from pregnant women was conducted to determine whether the
expression of CD300a in T lymphocytes changes in women presenting with anti-fetal
rejection.
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Materials and methods
Patient Samples
Whole peripheral blood was collected by venipuncture from healthy non-pregnant women
(N = 11) and normal pregnant women (N = 40). All normal pregnant women eventually
delivered babies at term (37+0 ~ 41+6 weeks) without any maternal and neonatal
complications such as intra-amniotic infection, hypertensive disorders, diabetes mellitus,
and small-for-gestational-age neonates. Cord blood (N = 17) was collected from the
umbilical vein during delivery; both maternal and cord blood samples were obtained in two
cases. All patients provided written informed consent, and the collection and use of the
samples were approved by the Institutional Review Boards of the participating institutions.
Cell Isolation/Sorting
Peripheral blood mononuclear cells (PBMCs) were isolated from samples of the peripheral
blood of healthy non-pregnant women by discontinuous density gradient centrifugation
using Histopaque 1077 and Histopaque 1119 (Sigma-Aldrich, St. Louis, MO, USA), and
labeled with CD300a-PE (Beckman Coulter, Miami, FL, USA), CD3-FITC (BD
Biosciences, San Jose, CA, USA), CD4-APC (BD Biosciences), and CD8-APC-CY7 (BD
Biosciences). CD4+CD300a-, CD4+CD300a+, CD8+CD300a-, and CD8+CD300a+ T
lymphocyte subsets were sorted using a FACSAria III cell sorter (BD Biosciences). The
purity of sorted cells ranged from 80.3 to 98.4%.
Microarray Analysis
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA),
according to the manufacturer’s instructions. DNase-treated total RNA (500 ng) was
amplified and biotin-labeled with the Illumina TotalPrep RNA Amplification Kit (Ambion,
Austin, TX, USA). Labeled cRNAs were hybridized to Illumina’s HumanHT-12 Expression
BeadChip (Illumina, San Diego, CA, USA). BeadChips were imaged using a BeadArray
Reader, and raw data were obtained with BeadStudio Software V.3.4.0 (Illumina). Gene
expression data was quantile normalized,20 probes non-detected in at least three samples
were removed, and differential expression was tested using a paired moderated t-test.21 A
threshold of 5% on the False Discovery Rate22 adjusted P values (called q-values) together
with a minimum of 1.5-fold change was used to determine significance. Gene ontology
analysis was performed using enrichment methods previously described23, 24 while pathway
analysis was conducted with the Signaling Pathway Impact Analysis (SPIA) method.25, 26
The complete data set is available in a MIAME (Minimal Information about a Microarray
Experiment) compliant format in ArrayExpress (http://www.ebi.ac.uk/arrayexpress/)
database (entry ID: E-TABM-902).
Real-time Quantitative RT-PCR (qRT-PCR)
Reverse transcription of total RNA was done using SuperScript III Reverse Transcriptase
(Invitrogen, Carlsbad, CA, USA) and oligo(dT) primers. qRT-PCR analyses were performed
with TaqMan gene expression assays (CCL5, Hs00174575_m1; CCR7, Hs99999080_m1;
CD244, Hs00175569_m1; CD300a, Hs00381974_m1; CX3CR1, Hs00365842_m1; GNLY,
Hs00246266_m1; GZMB, Hs00188051_m1; GZMK, Hs00157878_m1; INFG,
Hs99999041_m1; IL15, Hs99999039_m1; ITGB1, Hs01127543_m1; KLRG1,
00929964_m1; PRF1, Hs00169473_m1; SLAMF7, Hs00221793_m1; Applied Biosystems,
Austin, TX, USA) using a Biomark System (Fluidigm, South San Francisco, CA, USA). The
human ribosomal protein, large, P0 (RPLP0; Applied Biosystems) was used for
normalization.
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Flow Cytometry
Peripheral blood in EDTA (100 µl) was incubated with a combination of CD300a-PE, CD3-
FITC, CD45RA-FITC (BD Biosciences), CCR7-PE-CY7 (BD Biosciences), CD4-APC, and
CD8-APC-CY7. Analyses were performed with the BD FACS LSR II flow cytometer and
BD FACSDiva software (BD Biosciences). For intracellular staining of granzyme A,
granzyme B, and perforin, 100 µl of whole blood were first labeled with antibodies against
surface antigens [CX3CR1-FITC (Biolegend, San Diego, CA, USA), CD300a-PE, CD3-PE-
CY7 (BD Biosciences), and CD4-APC-CY7 (Biolegend) or CD8-APC-CY7]. After lysis
with 1X FACS Lysing Solution (BD Biosciences) and fixation/permeabilization with
Fixation/Permeablization solution (BD Biosciences), the cells were stained with Granzyme
A-Alexa Fluor 700 (Biolegend), Granzyme B-Alexa Fluor 647 (Biolegend), and Perforin-
PerCp-Cy5.5 (Biolegend).
Placental Pathology
Four hematoxylin-and-eosin stained sections (two full-thickness sections of the placental
disc, one umbilical cord section, and one roll of chorioamniotic membranes) were reviewed
for the presence of placental pathologic findings according to the criteria proposed by the
Perinatal Section of the Society for Pediatric Pathology. Placental histological changes were
categorized as those associated with amniotic fluid infection (acute chorioamnionitis),
maternal vascular underperfusion, and fetal vascular obstruction.27–30 Villitis of unknown
etiology, chronic deciduitis, and chronic chorioamnionitis were diagnosed according to
previously described criteria.19, 31, 32
Statistical Analysis
For continuous variables, distributions were examined for normality using Kolmogorov-
Smirnov tests. When data were far from normality, the Mann-Whitney U test was performed
for independent variables, and the Wilcoxon signed rank test was used for related variables.
Statistical analyses were performed using SPSS Version 19.0 (SPSS, Inc., Chicago, IL,
USA). All P values were two-sided, and a value of P < 0.05 was considered to be
statistically significant.
Results
Transcriptome of CD300a+ and CD300a− T Lymphocytes
Microarray analyses of CD300a+CD8+ T lymphocytes and CD300a−CD8+ T lymphocytes
from peripheral blood of five healthy adult women revealed differential regulation of 1,245
genes out of more than 25,000 annotated genes on the array (adjusted P value < 0.05, fold
change > 1.5) (Figure 1a, 1c). Gene Ontology (GO) analysis showed enrichment of 141
biological processes, largely related to immune process, cell death, and signal transduction
(Table I). One hundred thirty-six genes were differentially expressed among 613 genes
associated with the immune system process (Table II). The impact evidence captured by
SPIA from signaling perturbations and enrichment revealed eight pathways such as
cytotoxicity and cytokine-cytokine receptor interaction (Table I).
On the contrary, a relatively smaller number of genes (123 genes) was found to be
differentially expressed between CD300a+ and CD300a−CD4+ T lymphocytes than in
CD8+ T lymphocytes (Figure 1b, 1c). On GO analysis, 63 biological processes were
enriched including signal transduction, immune response, and cell communication, which
were similar to those for CD300a+CD8+ T lymphocytes (Table III). Among the genes
related to the immune process, 16 genes were differentially expressed in CD300a+CD4+ T
lymphocytes (Table IV). Cytokine-cytokine receptor interaction was found to be enriched by
the SPIA pathway analysis.
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Among the differentially expressed genes between CD300a+CD4+ and CD300a−CD4+ T
lymphocytes, 87 genes were regulated in the same direction as in the comparison between
CD300a+CD8+ and CD300a−CD8+ T lymphocytes. The gene FCRL3, down-regulated in
CD300a+CD4+ T lymphocytes compared to CD300a−CD4+ T lymphocytes, was found to
be up-regulated in CD300a+CD8+ compared to CD300a-CD8+ T lymphocytes (Figure 1d).
Differential mRNA Expression of Immune-related Genes between CD300a+ and CD300a−
CD8+ T Lymphocytes
Chemokines/Cytokines—Among chemokine genes, CCL3, CCL5, and CCL20 showed
an increased mRNA expression in CD300a+CD8+ T lymphocytes, whereas mRNA
expression of CXCL16 was decreased in CD300a+CD8+ T lymphocytes compared to
CD300a-CD8+ T lymphocytes. mRNA expression of some cytokines of the hematopoietin
family, including interleukins, were up-regulated in CD300a+CD8+ T lymphocytes. These
included IL15 sharing certain biological activities with IL-2 such as T and NK cell
activation and proliferation; IL29, a member of the IL-10 family; and CLCF1, a member of
the IL-6 family. mRNA expression of several members of the TNF family (TNF, TNFSF9,
TNFSF10, TNFSF12, TNFSF14, FASLG, and CD40LG) was up-regulated, while mRNA
expression of another member of the TNF family, LTB, was down-regulated in CD300a
+CD8+ T lymphocytes compared to CD300a−CD8+ T lymphocytes. Among the members
of the interferon family, mRNA expression of interferon-gamma (IFNG), interferon gamma-
inducible protein 16 (IFI16), and interferon-induced protein with tetratricopeptide repeat 2
(IFIT2), was up-regulated in CD300a+CD8+ T lymphocytes, while mRNA expression of
interferon-induced transmembrane protein 3 (IFITM3) was down-regulated.
Chemokine/Cytokine Receptors—Among chemokine receptor genes, mRNA
expression of CXCR3 (a receptor for CXCL9, −10, and −11), CXCR6 (a receptor for
CXCL16), CX3CR1 (a receptor for CX3CL1), and CCR6 (a receptor for CCL20) was up-
regulated in CD300a+CD8+ T lymphocytes compared to CD300a− cells, while mRNA
expression of CCR7 (a receptor for CCL19 and -21) was down-regulated. Regarding
interleukin receptor genes, mRNA expression of IL10RA, IL12RB1, IL18R1, IL18RAP, and
IL28RA was up-regulated in CD300a+CD8+ T lymphocytes, while mRNA expression of
IL6R and IL11RA were down-regulated. Among TNF receptor genes, mRNA up-regulation
of TNFRSF1B, TNFRSF4, FAS, and TNFRSF9 was observed in CD300+CD8+ T
lymphocytes, whereas mRNA expression of CD27 (TNFRSF7), TNFRSF25, and
ectodysplasin A receptor (EDAR) was down-regulated. mRNA expression of interferon
gamma receptor 2 (IFNGR2) and TGFBR2 was down-regulated in the CD300+ subset.
Effector Molecules for Cytotoxicity—One of the major effector functions of cytotoxic
T lymphocytes is secretion of cytotoxic granules to induce apoptosis of target cells. mRNA
expression of the major components of the granzyme genes (GZMA, GZMB, and GZMK)
was up-regulated in CD300+CD8+ T lymphocytes. mRNAs of granulysin (GNLY) and
perforin (PRF1) were also highly expressed in CD300+CD8+ T lymphocytes.
Killer Cell Receptors—CD300+CD8+ T lymphocytes showed the enriched mRNA
expression of killer cell receptors. A subset of killer cell immunoglobulin-like receptors
(KIR2DL1, −2, −3, −4, −5A, KIR2DS5, KIR3DL1, −2, and −3) and killer cell lectin-like
receptors (KLRA1, −B1, −C1, −C3, −D1, −F1, and −G1) showed increased mRNA
expression in CD300a+CD8+ T lymphocytes. Among inhibitory killer cell receptors, mRNA
expression of KIR3DL1, KIR3DL2, KIR2DL, and KLRC1/KLRD1 (CD94) were up-
regulated. Among activating killer cell receptors, mRNA expression of KIR2DS and
KLRC3/KLRD1 (CD94) were up-regulated. mRNA expression of NCR3 (NKp30) and
CD244, among other membrane receptors, was also upregulated.
Xu et al. Page 5
Am J Reprod Immunol. Author manuscript; available in PMC 2013 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Differential mRNA Expression of Immune-related Genes between CD300a+CD4+ and
CD300a−CD4+ T Lymphocytes
Among genes related to the immune process, 16 genes were differentially expressed in
CD300a+CD4+ T lymphocytes (Table IV). Among the differentially expressed immune-
related genes between CD300a+CD4+ and CD300a−CD4+ T lymphocytes, 12 genes were
regulated in the same direction as those expressed differentially between CD300a+CD8+
and CD300a−CD8+ T lymphocytes: CD300a, IL15, CCL5, TIMP1, TNFRSF4, CD226,
GZMA, IFNG, TNFSF14, APOBEC3G, CFH, and CTSW. Four genes differentially
expressed only in CD300a+CD4+ T lymphocytes, but not in CD300a+CD8+ T
lymphocytes, were CTLA4, OSM, GPR44, and TNFSF13B. CTLA4 was down-regulated
but the others were up-regulated in CD300a+CD4+ T lymphocytes compared to CD300a
−CD4+ T lymphocytes.
Validation of Differential Expression of Immune-related Genes in CD300a+ T Lymphocytes
For validation of the microarray results, the differential mRNA expressions of the selected
genes (CCL5, CCR7, CD244, CD300a, CX3CR1, GLNY, GZMB, GZMK, IFNG, IL15,
ITGB, KLRG1, PRF1, and SLAMF7), related to cytotoxicity and cytokine-cytokine receptor
interaction, between peripheral CD300a+ and CD300a−CD8+ T lymphocytes (N = 9), were
analyzed by qRT-PCR. All genes other than CCR7 were expressed significantly higher in
CD300a+CD8+ T lymphocytes than in CD300a−CD8+ T lymphocytes, while the expression
of CCR7 was lower in CD300a+CD8+T lymphocytes than in CD300a−CD8+ T
lymphocytes, which confirmed the microarray analysis (Figure 2).
Granzyme A, granzyme B, perforin, and CX3CR1 protein expressions in peripheral CD300a
+ and CD300a−CD8+ T lymphocytes (N = 30) were also assessed by flow cytometry, all of
which were expressed higher in the CD300a+ sub-population than in the CD300a- sub-
population (Figure 3).
CD300a+ T Lymphocytes in Peripheral Blood of Pregnant Women
The demographic characteristics of the study population are shown in Table V. On flow
cytometric analysis of peripheral blood from pregnant women (N = 19), CD300a was
detected in 26.6% (5.9–65.2%) of CD8+ lymphocytes and in 18.3% (8.4–67.3%) of CD4+ T
lymphocytes. When evaluated in subsets of Tc and Th lymphocytes by co-labeling for
CD45RA and CCR7,33 the proportion of CD300a+ cells was greater in the order of effector,
effector memory, central memory, and naïve T lymphocytes (N = 40, Figure 4a, 4b). The
proportion of CD300a+ T lymphocytes was not different between preterm and term pregnant
women [preterm (N = 7) vs. term (N = 12): CD8+, 30.4% (11.7–41.6%) vs. 19.7% (5.9–
65.2%); and CD4+, 21.9% (14.0–67.3%) vs. 18.3% (8.4–48.1%)]. The proportions of
CD300a+ T lymphocytes in cord blood of neonates (N = 17) were quite small [CD8+, 7.3%
(1.4–17.9%); CD4+, 6.1% (1.3–18.1%)], compared to those in adults (P < 0.001).
We analyzed the proportion of the CD300a+ subset of T lymphocytes in samples of the
peripheral blood of pregnant women according to placental pathology findings: intra-
amniotic infection, maternal vascular underperfusion, fetal vascular thrombo-occlusive
diseases, and chronic placental inflammation (villitis of unknown etiology, chronic
chorioamnionitis, and chronic deciduitis). The median sampling to delivery interval was 1
day (range: 0–194 days). The proportion of CD300a+CD8+ T lymphocytes was higher in
cases with chronic chorioamnionitis than in those without chorioamnionitis (Figure 4c).
When evaluated in subsets of Tc and Th lymphocytes by co-labeling for CD45RA and
CCR7,33 the proportion of CD300a+ cells was greater in the effector memory and the
central memory subsets of CD8+ T lymphocytes but not in either effector or naïve subsets
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(Figure 4e). The other placental findings were not associated with changes in CD300a+
peripheral T lymphocytes.
Discussion
This study reports the transcriptome of CD300a+CD8+ and CD300a+CD4+ T lymphocytes
for the first time. The principal findings of this study are: 1) CD300a expression defines a
distinct sub-population of CD8+ T lymphocytes; 2) the gene expression profile of CD300a
+CD8+ T lymphocytes is consistent with a more cytotoxic phenotype than that of CD300a-
CD8+ T lymphocytes; and 3) the proportion of CD300a+ peripheral Tc lymphocytes is
significantly increased in pregnant women with chronic chorioamnionitis (anti-fetal cellular
rejection of the chorioamniotic membranes) than in women without chronic
chorioamnionitis.
Significance of CD300a Expression in CD8+T Lymphocytes
CD300a is constitutively expressed in granulocytes, NK cells, and dendritic cells, in which it
functions as an inhibitory receptor.34–39 Co-ligation of CD300a exerts an inhibitory effect
on CD32a–mediated signaling in neutrophils.34 In mast cells, CD300a inhibits kit-mediated
SCF-induced signaling to cause impairment of differentiation, survival, and activation.35
CD300a also suppresses eotaxin-dependent transmigration of eosinophils and the anti-
apoptotic effects of IL-5 and GM-CSF.39 CD300a cross-linking inhibits the cytotoxicity of
NK cells.36, 38 In dendritic cells, CD300a inhibits TNF-α production from activated
plasmacytoid dendritic cells and up-regulates type I IFN production.37 In contrast to non-
lymphocytic leukocytes, only a subset of B and T lymphocytes was found to express
CD300a.16–18
In this study, the majority of CD300a+CD8+ T lymphocytes were memory and effector cells
as was the case with CD4+ T lymphocytes.17 Fetal T lymphocytes, most of which are of a
naïve subset, were almost negative for CD300a. Interestingly, far more genes were
differentially expressed between CD300a+CD8+ and CD300a−CD8+ T lymphocytes than
between CD300a+CD4+ and CD300a−CD4+ T lymphocytes. This suggests that CD300a is
biologically more significant in CD8+ T lymphocytes than in CD4+ T lymphocytes. This is
in contrast to the comparison of the transcriptional profiles between activated CD4+ T
lymphocytes and CD8+ T lymphocytes, each group of which showed similar numbers of
differentially expressed genes.40
CD300a+CD8+ T lymphocytes had differential expressions of cytokine/chemokine and
related genes. CCL3 and CCL20 were up-regulated upon T lymphocyte activation and
responsible for the pro-inflammatory response of T lymphocytes, while CCL5 was highly
expressed in resting T lymphocytes, suggesting its importance in the homeostasis of resting
T lymphocytes.40 CXCL16 and CXCR6 are examples of co-expression of ligand and its
receptor in the same cell, and activation of T lymphocytes is known to lead to marked down-
regulation of CXCL16.41 In addition, IFNG, a major effector cytokine of T lymphocytes, is
up-regulated in CD300a+CD8+ T lymphocytes. Several key effector molecules for
cytotoxicity were also up-regulated in CD300a+CD8+ T lymphocytes. CD300a+CD8+ T
lymphocytes expressed GZMA, GZMB, and GZMK. GZMB is specific for effector-type
cells, while GZMK is found mainly in a subset of memory-type cells. GZMA is highly
expressed on primed CD8+ T lymphocytes regardless of differentiation status. High
expression of CX3CR1 is also compatible with the features of peripheral cytotoxic effector
CD8+ T lymphocytes with intracellular perforin and granzyme B.42
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Differential Expression of Immune-related Genes in CD300a+CD4 T Lymphocytes
A certain number of the genes (N = 87) shared by CD300a+CD4+ and CD300a+CD8+ T
lymphocytes reflect common cellular events shared by CD4+ and CD8+ T lymphocytes in
the CD300a+ sub-population. Four immune process-related genes differentially expressed
only in CD300a+CD4+ T lymphocytes, but not in CD300a+CD8+ T lymphocytes, were
CTLA4, OSM, GPR44, and TNFSF13B. CTLA4 is a co-stimulatory molecule expressed by
activated T lymphocytes and binds to B7-1 and B7-2 on antigen-presenting cells. CTLA4
transmits an inhibitory signal to T lymphocytes.43 Oncostatin M encoded by OSM is a
member of the IL-6 family acting as a growth regulator44 and as an inflammatory
mediator.45 Th1 lymphocytes regulate hematopoietic progenitor cell homeostasis by
production of oncostatin M.46 GPR44 encoding G-protein-coupled receptor 44 is selectively
expressed in Th2 cells.47 TNFSF13B encodes a cytokine of the tumor necrosis factor (TNF)
ligand family, which is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and
TNFRSF13C/BAFFR.
Changes in T Lymphocyte Immune Responses during Pregnancy
Most studies about T lymphocyte tolerance of the fetal allograft have been done mainly
about T-helper cells.48, 49 In earlier studies, maternal tolerance toward the fetal allograft was
explained by the predominant Th2 immunity over Th1 immunity.50 The Th1/Th2 theory is
now blending into the Th1/Th2/Th17/Treg paradigm, and the role of Treg cells is
increasingly emphasized.6, 51, 52
In contrast, studies about the changes of cytotoxic T lymphocytes during normal pregnancy
are limited.9–14 Alteration of cytotoxic T lymphocytes in pregnancy-related complications
such as implantation failures and preeclampsia supports the significance of cytotoxic T
lymphocytes for the successful maintenance of normal pregnancy.53–55 Yang et al. showed
increased peripheral CD8+T lymphocyte activation in women with multiple implantation
failures and recurrent pregnancy losses. The proportion of activated T lymphocytes was
inversely correlated with IFNγ/IL-10 producing CD3+/CD4+ T lymphocyte ratios.54 De
Groot et al. reported that women with preeclampsia had a higher partner-specific cytotoxic
T-lymphocytic precursor frequency when compared to women with uncomplicated
pregnancies, suggesting an increased cytotoxic T-cell response to paternal antigens in
women with preeclampsia.53
Chronic chorioamnionitis is a common placental lesion found in cases of late preterm birth,
and represents maternal anti-fetal cellular rejection involving the chorioamniotic
membranes.32, 56, 57 We demonstrated in this study that CD300a+CD8+ T lymphocytes are
mainly cytotoxic effector cells and memory cells, and the proportion of CD300a+CD8+ T
lymphocytes in peripheral blood was higher in pregnant women who subsequently delivered
placentas showing chronic chorioamnionitis than in those who did not. It suggests that
peripheral CD8+ T lymphocytes of pregnant women with chronic chorioamnionitis have
increased systemic cytotoxic capacity as a manifestation of maternal anti-fetal rejection. It is
intriguing that the pregnant women with villitis of unknown etiology (anti-fetal cellular
rejection involving the chorionic villi) did not show a significant increase of CD300a+ T
lymphocytes in peripheral blood.19 Further analysis of more cases would be necessary to
address this issue.
Conclusion
We report the transcriptome of CD300a+ peripheral T cells for the first time. The findings
herein strongly suggest a role for CD300a+CD8+ T cells in the maternal anti-fetal immune
response. There is a significant increase in the proportion of CD300a+CD8+ T cells in
women presenting with anti-fetal cellular rejection in the chorioamniotic membranes.
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Figure 1.
The transcriptome of CD300a+ and CD300a− T lymphocytes. (a, b) Volcano plots showing
the relationship between the FDR-corrected P values of the genes (−log 10 of) and their fold
changes (log2 of). Blue dots outside the two red lines and above the gray line have fold
changes >1.5 and FDR-corrected P values < 0.05. Positive values on the x-axis indicate
genes whose expression increased in CD300+ T lymphocytes, while negative values indicate
genes down-regulated in CD300a+ T lymphocytes. (a: CD8+ T lymphocytes; b: CD4+ T
lymphocytes) (c) A principal component analysis plot generated with data from five pairs of
samples (CD300+CD8+ (pink), CD300a−CD8+ (gray), CD300a+CD4+ (black), CD300a
−CD4+ (blue) T lymphocytes), showing a more clear segregation between CD300a+CD8+
and CD300a−CD8+ than between CD300a+CD4+ and CD300a−CD4+ T lymphocytes. (d)
Among the differentially expressed genes between CD300a+CD8+ and CD300a−CD8+ T
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lymphocytes, 87 genes were regulated in the same direction as those expressed differentially
between CD300a+CD4+ and CD300a−CD4+ T lymphocytes. Far more significantly
enriched genes (N = 1,157) were identified in the CD8+ T lymphocytes with CD300a
expression, while only 35 more genes were differentially regulated in the CD4+ T
lymphocytes with CD300a expression.
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Figure 2.
Validation of microarray analysis to compare gene expression between CD300a+CD8+ and
CD300a−CD8+ T lymphocytes. Differential mRNA expression of the genes related to
cytotoxicity and cytokines-cytokine receptor interaction between CD300a+ and CD300a
−CD8+ T lymphocytes was confirmed by quantitative real-time-RT-PCR. CCR7 mRNA
expression was lower, whereas the others were higher in CD300a+ than in CD300a− CD8+
T lymphocytes.
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Figure 3.
Expression of cytotoxicity effector proteins in CD300a+CD8+ peripheral T lymphocytes.
Granzyme A (a), granzyme B (b), perforin (c), and CX3CR1 (d) were expressed higher in
CD300a+ than CD300a− CD8+ T lymphocytes. **, P < 0.01; ***, P < 0.001.
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Figure 4.
The proportion of CD300a+ T lymphocytes in peripheral blood by flow cytometry. (a,b) The
naïve, central memory, effector memory, and effector subsets of CD8+ T lymphocytes (a)
and CD4+ T lymphocytes (b) showed the gradual increase of CD300a expression. (c,d) The
increase of CD300a expression in pregnant women with chronic chorioamnionitis compared
to the expression in those without was detected in CD8+ T lymphocytes. (c: CD8+ T
lymphocytes; d: CD4+ T lymphocytes) (e) Central memory and effector memory CD8+ T
lymphocytes showed higher expression of CD300a in cases with chronic chorioamnionitis
than in those without. *, P < 0.05; **, P < 0.01; TcN, naïve cytotoxic T lymphocytes,
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TcCM, central memory cytotoxic T lymphocytes; TcEM, effector memory cytotoxic T
lymphocytes; TcE, effector cytotoxic T lymphocytes.
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Table I
Top 10 biological processes and 8 pathways enriched in CD300a+CD8+ T lymphocytes compared to CD300a-
CD8+ T lymphocytes
No. Enriched Genes / No. Total Genes Adjusted P value
Biologic process Immune system process 136/613 6.43E-16
Immune response 103/410 1.31E-15
Defense response 83/353 1.52E-10
Death 123/690 1.71E-07
Cell death 122/687 2.10E-07
Response to stimulus 244/1678 2.83E-07
Programmed cell death 114/650 1.31E-06
Apoptosis 113/646 1.59E-06
Signal transduction 293/2154 3.00E-06
Cell communication 312/2340 6.13E-06
Pathway Natural killer cell mediated cytotoxicity 35/104 7.19E-10
Graft-versus-host disease 21/37 8.47E-10
Cytokine-cytokine receptor interaction 40/146 1.51E-09
Antigen processing and presentation 24/68 3.54E-06
Allograft rejection 14/30 3.62E-05
Asthma 10/20 0.00070
Type I diabetes mellitus 13/33 0.00172
Autoimmune thyroid disease 12/35 0.00604
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Table II
Top 20 differentially expressed genes related to immune system process in CD300a+CD8+ lymphocytes
Gene Symbol Gene Name Fold Change Adjusted P value
CD300A CD300a molecule 9.00 5.86E-10
CD79A* CD79a molecule, immunoglobulin-associated alpha 2.98 5.86E-10
KIR2DL3 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3 11.82 1.71E-08
PLCG2 phospholipase C, gamma 2 (phosphatidylinositol-specific) 4.40 2.16E-08
HLA-DOA* major histocompatibility complex, class II, DO alpha 3.82 4.26E-08
CCL3 chemokine (C-C motif) ligand 3 3.81 4.26E-08
TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 3.17 6.53E-08
PRKCA* protein kinase C, alpha 3.35 7.78E-08
CCL3L3 chemokine (C-C motif) ligand 3-like 3 3.95 9.28E-08
SLAMF7 SLAM family member 7 1.99 1.10E-07
IL15 interleukin 15 2.53 1.16E-07
FYB* FYN binding protein (FYB-120/130) 1.84 1.37E-07
CD55* CD55 molecule, decay accelerating factor for complement (Cromer blood group) 2.99 1.53E-07
VIPR1* vasoactive intestinal peptide receptor 1 3.20 1.84E-07
TBK1 TANK-binding kinase 1 2.60 1.92E-07
APOBEC3F apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F 2.88 1.94E-07
CLCF1 cardiotrophin-like cytokine factor 1 2.90 3.25E-07
DLL1* delta-like 1 (Drosophila) 2.70 3.46E-07
TGFBR2* transforming growth factor, beta receptor II (70/80kDa) 2.02 3.79E-07
MAPK1 mitogen-activated protein kinase 1 2.26 4.09E-07
*down-regulated
Am J Reprod Immunol. Author manuscript; available in PMC 2013 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Xu et al. Page 21
Table III
Top 10 biological processes and the pathway enriched in CD300a+CD4+ T lymphocytes compared to CD300a
−CD4+ T lymphocytes
No. Enriched Genes / No. Total Genes Adjusted P value
Biologic process Signal transduction 41/2154 0.00449
Immune response 15/410 0.00449
Negative regulation of smooth muscle cell proliferation 3/6 0.00449
Smooth muscle cell proliferation 4/17 0.00449
Regulation of smooth muscle cell proliferation 4/17 0.00449
Cell communication 42/2340 0.00455
Response to external stimulus 15/438 0.00455
Response to stimulus 33/1678 0.00731
Response to wounding 11/267 0.00888
Muscle cell proliferation 4/24 0.00950
Pathway Cytokine-cytokine receptor interaction 9/146 4.76E-05
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Table IV
Differentially expressed genes related to immune system process in CD300a+CD4+ lymphocytes
Gene Symbol Gene Name Fold Change Adjusted P value
CD300A CD300a molecule 5.57 6.53E-08
CTLA4* cytotoxic T-lymphocyte-associated protein 4 1.79 1.17E-04
IL15 interleukin 15 1.96 1.68E-04
CCL5 chemokine (C-C motif) ligand 5 7.21 4.58E-04
TIMP1 TIMP metallopeptidase inhibitor 1 2.00 4.58E-04
TNFRSF4 tumor necrosis factor receptor superfamily, member 4 2.05 2.97E-03
OSM oncostatin M 1.95 3.53E-03
CD226 CD226 molecule 1.64 8.41E-03
GZMA granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) 3.70 1.11E-02
GPR44 G protein-coupled receptor 44 1.64 1.51E-02
IFNG interferon, gamma 2.13 1.86E-02
TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 1.55 2.17E-02
APOBEC3G apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G 1.76 2.95E-02
TNFSF13B tumor necrosis factor (ligand) superfamily, member 13b 1.54 3.33E-02
CFH complement factor H 1.73 4.08E-02
CTSW cathepsin W 1.61 4.98E-02
*down-regulated
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Table V
Demographics and clinical characteristics of pregnant women
Maternal age (years) (median, range) 25 (15–40)
Gestational age at sampling (weeks) (median, range) 39.0 (13.3 – 41.7)
Gestational age at delivery (weeks) (median, range) 39.7 (37.0 – 41.9)
Labor at sampling (present/absent/unknown) 14/25/1
Race (African American /others/unknown) 35/4/1
Para (primiparity/multiparity) 13/27
Baby gender (male/female) 17/23
Smoking (yes/no) 3/37
Interval between sampling and delivery (days) (median, range) 1 (0–194)
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